Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Emerson

Showing results (231-240 of 247) with videos related to

Pageof 25
Sort By:
Obesity (Silver Spring, Md.)|December 11, 2022
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristicsIldiko Lingvay, Kirstine Brown-Frandsen, Helen M Colhoun, et al.
Diabetologia|September 16, 2017
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortalityThomas R Pieber, Steven P Marso, Darren K McGuire, et al.
Critical Care Medicine|July 8, 2009
Implementation of a mandatory checklist of protocols and objectives improves compliance with a wide range of evidence-based intensive care unit practicesMatthew C Byrnes, Douglas J E Schuerer, Marilyn E Schallom, et al.
Diabetes Care|March 29, 2025
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized TrialsMatthew M Y Lee, Naveed Sattar, Rodica Pop-Busui, et al.
Resuscitation|April 21, 2010
Increased survival after EMS witnessed cardiac arrest. Observations from the Resuscitation Outcomes Consortium (ROC) Epistry-Cardiac arrestDavid Hostler, Elizabeth G Thomas, Scott S Emerson, et al.
The New England Journal of Medicine|November 12, 2023
Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesA Michael Lincoff, Kirstine Brown-Frandsen, Helen M Colhoun, et al.
Lancet (London, England)|September 2, 2024
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trialsMikhail N Kosiborod, John Deanfield, Richard Pratley, et al.
Lancet (London, England)|August 24, 2024
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialJohn Deanfield, Subodh Verma, Benjamin M Scirica, et al.
Diabetes Care|June 22, 2024
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT TrialSteven E Kahn, John E Deanfield, Ole Kleist Jeppesen, et al.
Lancet (London, England)|October 25, 2025
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trialJohn Deanfield, A Michael Lincoff, Steven E Kahn, et al.
Pageof 25

Showing results (231-240 of 247) with videos related to

Sort By:
Pageof 25
Obesity (Silver Spring, Md.)|December 11, 2022
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristicsIldiko Lingvay, Kirstine Brown-Frandsen, Helen M Colhoun, et al.
Diabetologia|September 16, 2017
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortalityThomas R Pieber, Steven P Marso, Darren K McGuire, et al.
Critical Care Medicine|July 8, 2009
Implementation of a mandatory checklist of protocols and objectives improves compliance with a wide range of evidence-based intensive care unit practicesMatthew C Byrnes, Douglas J E Schuerer, Marilyn E Schallom, et al.
Diabetes Care|March 29, 2025
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized TrialsMatthew M Y Lee, Naveed Sattar, Rodica Pop-Busui, et al.
Resuscitation|April 21, 2010
Increased survival after EMS witnessed cardiac arrest. Observations from the Resuscitation Outcomes Consortium (ROC) Epistry-Cardiac arrestDavid Hostler, Elizabeth G Thomas, Scott S Emerson, et al.
The New England Journal of Medicine|November 12, 2023
Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesA Michael Lincoff, Kirstine Brown-Frandsen, Helen M Colhoun, et al.
Lancet (London, England)|September 2, 2024
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trialsMikhail N Kosiborod, John Deanfield, Richard Pratley, et al.
Lancet (London, England)|August 24, 2024
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialJohn Deanfield, Subodh Verma, Benjamin M Scirica, et al.
Diabetes Care|June 22, 2024
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT TrialSteven E Kahn, John E Deanfield, Ole Kleist Jeppesen, et al.
Lancet (London, England)|October 25, 2025
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trialJohn Deanfield, A Michael Lincoff, Steven E Kahn, et al.
Pageof 25